Itraconazole trial for esophageal cancer response
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 2 trial tests whether itraconazole (an antifungal medicine) can help people with localized esophageal or gastroesophageal junction cancer achieve a better “pathologic complete response,” meaning no remaining cancer found after treatment. You may be considered if your cancer is in a localized/locoregional stage and you meet key safety checks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have localized (locoregional) esophageal cancer, or localized (locoregional) cancer at the gastroesophageal junction
- You can provide informed consent (you are willing and able to join)
- Your heart rhythm measurement (QTc) is not over 450 milliseconds
- You do not have a history of symptomatic congestive heart failure
- Your liver blood tests are no more than 3 times the upper limit of normal (LFTs ≤ 3×ULN)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests a combination of chemotherapy (5-FU/leucovorin plus irinotecan and oxaliplatin) together with radiation for certain types of esophagus/stomach-junction cancer. It may help shrink tumors and control cancer that is locally advanced but not spread to distant organs.
This study tests whether adding itraconazole (an anti-fungal medicine) to standard chemo-radiation before surgery increases the chance of complete tumor response. It’s for people with esophageal (or GE junction) cancer that can be removed with curative surgery after treatment.
This trial tests if adding the antifungal drug itraconazole to standard ablation therapy can help prevent esophageal cancer in people with high-risk Barrett's esophagus. You must have a confirmed diagnosis of Barrett's esophagus with low- or high-grade dysplasia or early-stage cancer, and be planning to have ablation treatment.
This trial checks if a drug called itraconazole affects how your body processes another drug, HS-20093. It is for people with advanced solid tumors who have tried standard treatments or cannot tolerate them.
This study tests how the body handles the study drug AZD5335 when taken with itraconazole (a common antifungal). It is for people with platinum-resistant ovarian, primary peritoneal, or fallopian tube cancer who have already tried standard treatments.
This trial tests a combination of two chemotherapy drugs (liposomal irinotecan and 5-FU) for people whose esophageal cancer didn't respond to or couldn't tolerate the first treatment. The goal is to see if this second-line therapy can shrink tumors or slow their growth.
Hear when a new Esophagus Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.